NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

You mean PFS that was NWBO's primary endpoint before they failed to meet it and threw it out?? That PFS??

PFS is an fully approvable endpoint by regulators and is commonly used in GBM clinical trials. Even Dr. Liau is using PFS as the lead efficacy endpoint in her Keytruda/DCVax-L combination trial -- did you miss that??

The NWBO OS is confounded by the crossover when patients were all double dosed while comparator was not (internal and external). Regulators are certainly going to question the validity of the OS data because of the confounding.